Potential Cardiovascular Benefits in the General Population of Men with ED, in Diabetics, in Men with Other Risk Factors: Are PDE-5 Inhibitors Cardioprotective?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Potential Cardiovascular Benefits in the General Population of Men with ED, in Diabetics, in Men with Other Risk Factors: Are PDE-5 Inhibitors Cardioprotective?

By "Princeton 4: PDE5 Inhibitors and Cardiac Health Symposium.” Huntington Medical Research Institutes, Pasadena, CA. Friday, March 10th, 2023. FEATURING Robert Kloner

0 views

July 11, 2023

Speaker Name and Title: Robert A. Kloner MD, PhD, CSO
The Princeton 4 meeting was ...
read more ↘ sponsored by an unrestricted grant from Sanofi.
Sanofi was not involved in choosing the content or speakers for the meeting.

Affiliation of the speaker:
HMRI and Keck School of Medicine of USC.

Title of the speaker’s talk: “Potential cardiovascular benefits in general population of men with ED, in diabetics, in men with other risk factors. Are PDE-5 inhibitors cardioprotective?”

Financial disclosure/Conflict of Interest:
- Dr. Kloner is a paid consultant for Sanofi
- Sanofi provided a grant to carry out Dr. Kloner's study on PDE-5 inhibitors and CV outcomes.
- Dr. Kloner did not receive a consulting fee from Sanofi for that study, nor for carrying out the Princeton 4 meeting.
↖ read less

Comments 0